<DOC>
	<DOCNO>NCT02797288</DOCNO>
	<brief_summary>The protocol aim address basic mechanism Clostridium difficile pathogenesis identify Clostridium difficile toxin inhibit eosinophils otherwise would protect gut damage . This could lead new effective approach treatment prevention Clostridium difficile colitis act downstream fecal microbiota transplant ( FMT ) next generation probiotic . Successful fecal transplantation restore Interleukin-25 , Interleukin-4 eosinophils colon</brief_summary>
	<brief_title>Immune Response FMT C.Difficile</brief_title>
	<detailed_description>Biopsies obtain random area sigmoid colon subject time fecal transplantation . Follow-up biopsy obtain sigmoid colon convalescence 60 day fecal transplant subject agree return optional 60 day follow-up . Biopsies take research purpose colonoscopy analyze : cytokine chemokines , gene expression analysis , immunohistochemistry high dimensional flow-cytometry .</detailed_description>
	<criteria>one relapse Clostridium difficile colitis eligible fecal microbiota transplant Unwilling biopsy research conduct time FMT Concurrent participation another clinical trial , except outcome FMT study Clinical contraindication colonoscopy , FMT , flexible sigmoidoscopy conscious sedation Pregnancy Inability give inform consent Incarceration Antibiotics unless discontinue 48 hour prior FMT Celiac disease form inflammatory bowel disease HIV infection Neutropenia ( &lt; 1000 PMNs/Âµl blood ) Concurrent participation another clinical trial , except outcome FMT study Anticoagulants able discontinue 5 day prior endoscopy flexible sigmoidoscopy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>